Skip to main content

Table 2 Results of 68Ga-PSMA PET/CT and 18FDG PET/CT

From: 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617

No.

Primary tumor

Moment of scan

Site

(Median) SUVmax

Range

PSMA

FDG

1

2008

2017

No pathological uptake

 

2018

Leptomeningeal/drop metastases Th10

2.66

 

2.66

2018

No pathological uptake

 

2

2008

2017

Lungs

 

5.02

4.46–5.35

Th4

 

2.94

2.94

2017

Lungs

 

5.45

4.54–7.99

Th4

 

2.79

2.79

2017

Left cervical lymph nodes

3.33

 

3.04–3.61

Lungs

8.03

 

7.65–9.40

Liver

7.18

 

5.84–8.52

2017

Left cervical lymph nodes

3.82

 

2.90–4.73

Decrease in lungs

8.67

 

6.56–10.56

Decrease in liver

6.01

 

6.01

2018

Unchanged left cervical lymph nodes

 

4.20

4.00–2.40

Increase in lungs

 

5.44

5.07–8.16

3

2013

2016

Lungs

 

1.85

0.93–2.66

2017

Lungs

3.61

 

1.31–4.66

2018

Recurrence/metastasis central compartment

 

3.61

3.61

Lungs

 

3.21

2.27–4.89

4

2010

2016

Residual thyroid bed

 

4.55

4.55

Lungs

 

4.44

2.51–7.51

Mediastinal/hilar lymph nodes

 

15.31

11.03–26.24

Lymph node m. pectoralis

 

1.93

1.93

Lymph node parasternal

 

1.37

1.37

2016

Residual thyroid bed

1.38

 

1.38

Lungs

1.54

 

1.28–1.79

Mediastinal/hilar lymph nodes

2.42

 

2.26–6.97

Lymph node m. pectoralis

0.85

 

0.85

5

1996

2016

Right cervical lymph nodes

4.35

 

3.56–5.13

Lungs

1.73

 

1.44–3.39

2017

Right cervical lymph nodes

 

3.35

2.12–8.36

Retropharyngeal

 

5.43

5.43

Lungs

 

2.85

1.83–3.76

2017

Right cervical lymph nodes

 

3.99

3.57–4.50

Retropharyngeal

 

5.82

5.82

Lungs

 

3.44

2.49–5.49

  1. Entries in bold are newly diagnosed on 68Ga-PSMA PET/CT